NORVAX UK is leading the development of UKvax Factory with the mRNA Universal Coronavirus Vaccine and is leading the mRNA UCV Consortium, Vaxcomm – The Vaccine FTO Commons.

The goal of the mRNA Universal Coronavirus Vaccine is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support innovation for future pandemic preparedness.

UKvax Factory plans to be a leading CDMO export business in the UK with planned cGMP capacity for delivery of 1.2 billion mRNA-UCV doses in 2022/23.

UKvax Factory and Norvax UK development of the mRNA Vaccine Platform in cooperation with SINTEF and strategic technology vendors, scientists at mRNA UCV Consortium, Norvax UK and UKvax Factory will program multiple mRNA targets on the virus for delivery of a Universal Coronavirus Vaccine for SARS-CoV-2 Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta VOCs, and expected future SARS-CoV-2 VOCs.

The mRNA Vaccine Platform for the mRNA UCV flagship product development, Norvax UK, mRNA UCV Consortium, and members of Vaxcomm – The Vaccine FTO Commons, are openly supported to apply the mRNA Vaccine Platform to develop novel mRNA vaccines for infectious disease, therapeutics and cancers.

The Mission of UKvax Factory by Norvax UK

Participating as a strategic partner in the global ecosystem for the transformative research, development and manufacture of safe and effective mRNA vaccines for global public health and pandemic preparedness and prevention.

Production of safe and effective mRNA Vaccines at industrial scale is planned to commence in 2022/23 for export to the UK, EU and international markets.

Learn More About Us

Visit Website
Visit Website
Visit Website
Visit Website
Visit Website